罗沙司他治疗肾衰竭贫血的随机试验:SIERRAS研究
主要疗效终点为第28至52周平均血红蛋白较基线变化,罗沙司他非劣于阿法依泊汀(最小二乘均值差0.48,95%CI 0.37-0.59,P<0.001),耐受性相当。
要点
- 罗沙司他在透析终末期肾病患者中非劣于阿法依泊汀。
- 第28至52周血红蛋白变化:罗沙司他0.39 vs 阿法依泊汀-0.09 g/dl。
- 两组耐受性可比,未报告新的安全性信号。
核心结论
- 在终末期肾病贫血患者中,罗沙司他治疗至52周非劣于阿法依泊汀,耐受性可接受。
主要发现
- 罗沙司他组370例,阿法依泊汀组371例,基线平均血红蛋白相似(10.30 g/dl,SD 0.66)。
- 第28至52周平均血红蛋白变化:罗沙司他0.39(SD 0.93)g/dl,阿法依泊汀-0.09(SD 0.84)g/dl。
- 罗沙司他非劣于阿法依泊汀,最小二乘均值差0.48(95%CI 0.37-0.59),P<0.001。
- 两组耐受性可比。
临床怎么用
- 对于接受促红细胞生成素治疗的透析终末期肾病贫血患者,罗沙司他可作为口服替代选择。
局限性
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Erythropoiesis-stimulating agents, standard of care for anemia of end-stage kidney disease, are associated with cardiovascular events. We evaluated the efficacy and safety of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. METHODS: SIERRAS was a phase 3, randomized, open-label, active-controlled study enrolled adults on dialysis for end-stage kidney disease receiving erythropoiesis-stimulating agents for anemia. Patients were randomized (1:1) to thrice-weekly roxadustat or epoetin alfa. Doses were based on previous epoetin alfa dose and adjusted in the roxadustat arm to maintain hemoglobin at ∼11 g/dl during treatment. Epoetin alfa dosing was adjusted per US package insert. Primary efficacy endpoint was mean hemoglobin (g/dl) change from baseline averaged over weeks 28 to 52. Treatment-emergent adverse events were monitored. RESULTS: Enrolled patients (roxadustat, n = 370 and epoetin alfa, n = 371) had similar mean (SD) baseline hemoglobin levels (10.30 [0.66] g/dl). Mean (SD) hemoglobin changes for weeks 28 to 52 were 0.39 (0.93) and -0.09 (0.84) in roxadustat and epoetin alfa, respectively. Roxadustat was noninferior (least squares mean difference: 0.48 [95% confidence interval: 0.37, 0.59]; P < 0.001) to epoetin alfa. Tolerability was comparable between treatments. CONCLUSION: In end-stage kidney disease, roxadustat was noninferior to epoetin alfa in up to 52 weeks of treatment in this erythropoietin-stimulating agent conversion study. Roxadustat had an acceptable tolerability profile.
引用
- Charytan C, Manllo-Karim R, Martin ER, et al. A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study. Kidney Int Rep. 2021. PMID: 34307977. doi:10.1016/j.ekir.2021.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。